Reuters logo
BRIEF-Ra Pharmaceuticals looks forward to advance oral small molecule C5 inhibitor program
November 30, 2016 / 12:20 PM / 10 months ago

BRIEF-Ra Pharmaceuticals looks forward to advance oral small molecule C5 inhibitor program

Nov 30 (Reuters) - Ra Pharmaceuticals Inc -

* “We also look forward to advancing our oral small molecule C5 inhibitor program through early development and toward an ind”

* “We are eager to initiate our phase 2 program in PNH patients in Q1 of 2017” Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below